NorthWest Biotherapeutics Inc (NWBO)

[hankmanhub]

I should note that when I posted on Oct 31, and Nov1, I was unaware of the guidance passed in October 2022 concerning
A tissue agnostic oncology drug [that] can therefore be used to treat multiple types of cancer (e.g., colorectal, thyroid, and breast cancers) with the targeted molecular alteration (e.g., either the same targeted molecular alteration or targeted molecular alterations affecting a single pathway)

But the idea is just plain common sense!
Imagine if the FDA approves DCVAX for nGBM and rGBM but then for technical reasons the FDA insists on many long trial for all of the other solid cancers which would delay cancer treatment with the safe DCVAX for many years or decades and which then prove out and eventually gain approval after many lives lost and many billions expended in the duration making the treatment that much more expensive! Imagine the outcry!